DB Schenker has extensive service expertise as an integrated logistics services provider. Expert teams connect the modules of the entire service range to form complex value chains, supporting industry and trade in the global exchange of goods. With Europe’s densest land transport network and top positions in the global air and ocean freight business DB Schenker is one of the market leaders worldwide. Roughly 65,000 employees at some 2,000 locations around the globe generated revenues totaling 14.943 billion euros in 2014. With about 3,000 employees, 22 logistics centres and offices at 17 strategic locations Schenker Logistics Nederland offers complete integrated services for land transport, air freight, ocean freight, contract logistics/supply chain management and fairs & events logistics in the Netherlands.
Contact
Schenker Logistics Nederland B.V.
Emma Goldmanweg 1, 5032
MN Tilburg
supplychainsolutions.nl@dbschenker.com
Tel: +31 (0)13 462 51 11
Juan Carlos Moro Rodríguez, CEO for the Iberia Cluster with DB Schenker, discusses the company’s plans to expand its reach across all forms of transport, offering logistics solutions rather than…
DB Schenker’s director of healthcare in Asia Pacific, Sugantha Natarajan describes the company’s presence across the region, while emphasizing the crucial need for localized solutions in specialized healthcare logistics. She…
DB Schenker’s Bart Coenen (BC) and Vincent Coolen (VC) explain the company’s Vision 2020 and talk about the benefits for pharma companies of outsourcing their supply chain. In 2013, DB…
Leadership in today’s pharmaceutical industry is no longer defined solely by the strength of a pipeline, but by the ability to anticipate change, execute consistently and adapt at scale. As…
As Synthon celebrates its 35th anniversary, the Dutch-headquartered complex generics specialist is entering a new phase of its evolution in the pursuit of affordable medicines worldwide. Having accelerated growth over…
Andreas Schuil, Vice President & General Manager EMEA at Orchard Therapeutics, discusses the company’s gene therapy for metachromatic leukodystrophy, a devastating ultra-rare paediatric disease. He highlights challenges in access, pricing…
Jay Iyer, CEO of the Access to Medicine Foundation, warns that rising nationalism and “onshoring” risk dismantling decades of progress in global health. As geopolitical tensions reshape how drugs are…
A century after insulin’s discovery transformed Type 1 diabetes from fatal to manageable, access remains deeply unequal. Writing exclusively for PharmaBoardroom, Access to Medicine Foundation CEO Jayasree Iyer explores why…
Philip Scheltens, Professor of Neurology and Partner and Head of the EQT Life Sciences Dementia Fund, reflects on the journey from founding the world’s first dedicated neurodegeneration investment fund to…
Globally some 1.8 million children and young people (CYP) live with type 1 diabetes (T1D) and in low-and middle-income countries (LMICs) prevalence of the disease is on the rise. In…
The 2024 Access to Medicine Index, released today, highlights some of the key milestones reached by global pharma in fostering access to their medicines in low- and middle-income countries (LMICs).…
The global pharma industry is facing increased pressure to ensure lifesaving medications reach underserved populations. Drawing from a new Access to Medicine Foundation report, AMF Head of Research Claudia Martinez…
Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access…
Marijn Verhoef, Director of Operations and Research at the Access to Medicine Foundation examines the interconnected challenges of drug shortages and antimicrobial resistance. Verhoef urges decisive and urgent action from…
The EMA’s Peter Arlett looks back on two years of the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to improve the environment for clinical trials…
See our Cookie Privacy Policy Here
